Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

IMPORTANCE: This analysis provides long-term follow-up in patients with BRAF wild-type advanced melanoma receiving first-line therapy based on anti–programmed cell death 1 receptor inhibitors. OBJECTIVE: To compare the 3-year survival with nivolumab vs that with dacarbazine in patients with previous...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Oncol
Egile Nagusiak: Ascierto, Paolo A., Long, Georgina V., Robert, Caroline, Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J., Hernberg, Micaela M., Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Cognetti, Francesco, Ny, Lars, Arance, Ana, Svane, Inge Marie, Schadendorf, Dirk, Gogas, Helen, Saci, Abdel, Jiang, Joel, Rizzo, Jasmine, Atkinson, Victoria
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2018
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439558/
https://ncbi.nlm.nih.gov/pubmed/30422243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.4514
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak